Roche and Monte Rosa join forces in $50M deal to revolutionize cancer and neuro discovery

Roche has entered into a partnership with start-up Monte Rosa Therapeutics, focusing on protein degradation. Roche will pay $50 million upfront to collaborate on Monte Rosa's "molecular glue" programs, which target proteins involved in the degradation process. The deal could potentially be worth over $2 billion in downstream biobucks for Roche.